APLS
Price
$28.59
Change
+$1.15 (+4.19%)
Updated
Jan 13 closing price
Capitalization
3.41B
49 days until earnings call
CYTK
Price
$46.71
Change
+$0.09 (+0.19%)
Updated
Jan 13 closing price
Capitalization
5.51B
37 days until earnings call
Ad is loading...

APLS vs CYTK

Header iconAPLS vs CYTK Comparison
Open Charts APLS vs CYTKBanner chart's image
Apellis Pharmaceuticals
Price$28.59
Change+$1.15 (+4.19%)
Volume$3.67M
Capitalization3.41B
Cytokinetics
Price$46.71
Change+$0.09 (+0.19%)
Volume$1.29M
Capitalization5.51B
APLS vs CYTK Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. CYTK commentary
Jan 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a StrongBuy and CYTK is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 14, 2025
Stock price -- (APLS: $28.59 vs. CYTK: $46.71)
Brand notoriety: APLS and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 118% vs. CYTK: 105%
Market capitalization -- APLS: $3.41B vs. CYTK: $5.51B
APLS [@Biotechnology] is valued at $3.41B. CYTK’s [@Biotechnology] market capitalization is $5.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $385.53B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 2 TA indicator(s) are bullish while CYTK’s TA Score has 4 bullish TA indicator(s).

  • APLS’s TA Score: 2 bullish, 4 bearish.
  • CYTK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than APLS.

Price Growth

APLS (@Biotechnology) experienced а -16.84% price change this week, while CYTK (@Biotechnology) price change was -5.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.85%. For the same industry, the average monthly price growth was -0.15%, and the average quarterly price growth was -4.30%.

Reported Earning Dates

APLS is expected to report earnings on May 01, 2025.

CYTK is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-5.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($5.51B) has a higher market cap than APLS($3.41B). CYTK YTD gains are higher at: -0.702 vs. APLS (-10.404). APLS has higher annual earnings (EBITDA): -209.71M vs. CYTK (-481.94M). CYTK has more cash in the bank: 1.01B vs. APLS (397M). APLS has less debt than CYTK: APLS (470M) vs CYTK (790M). APLS has higher revenues than CYTK: APLS (715M) vs CYTK (3.22M).
APLSCYTKAPLS / CYTK
Capitalization3.41B5.51B62%
EBITDA-209.71M-481.94M44%
Gain YTD-10.404-0.7021,483%
P/E RatioN/AN/A-
Revenue715M3.22M22,212%
Total Cash397M1.01B39%
Total Debt470M790M59%
FUNDAMENTALS RATINGS
APLS vs CYTK: Fundamental Ratings
APLS
CYTK
OUTLOOK RATING
1..100
2379
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10048
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6583
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APLS's Valuation (75) in the Medical Distributors industry is in the same range as CYTK (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (48) in the Biotechnology industry is somewhat better than the same rating for APLS (100) in the Medical Distributors industry. This means that CYTK’s stock grew somewhat faster than APLS’s over the last 12 months.

APLS's SMR Rating (98) in the Medical Distributors industry is in the same range as CYTK (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to CYTK’s over the last 12 months.

APLS's Price Growth Rating (65) in the Medical Distributors industry is in the same range as CYTK (83) in the Biotechnology industry. This means that APLS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for APLS (100) in the Medical Distributors industry. This means that CYTK’s stock grew significantly faster than APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSCYTK
RSI
ODDS (%)
N/A
Bullish Trend 7 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
83%
Momentum
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 7 days ago
81%
MACD
ODDS (%)
N/A
Bullish Trend 7 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
75%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
Bearish Trend 16 days ago
79%
Bearish Trend 7 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 7 days ago
84%
Aroon
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
83%
View a ticker or compare two or three
Ad is loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LRSRX13.500.13
+0.97%
Lord Abbett Small Cap Value R3
BKTSX26.670.05
+0.19%
iShares Total US Stock Market Idx K
FCIAX57.500.06
+0.10%
American Funds Invmt Co of Amer 529-F-2
SRFMX13.98N/A
N/A
Sarofim Equity
ISMOX4.07-0.02
-0.49%
Voya MidCap Opportunities Port S

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with PGEN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then PGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+4.19%
PGEN - APLS
42%
Loosely correlated
-8.94%
IGMS - APLS
38%
Loosely correlated
-15.07%
ROIV - APLS
37%
Loosely correlated
+1.03%
RCKT - APLS
37%
Loosely correlated
-3.68%
ACLX - APLS
36%
Loosely correlated
-2.49%
More